{"pressItemDictionary": {"Press Releases": [{"Title": "Update On Local Covid-19 Situation and Vaccination Progress (17 August 2021)", "PublishedDate": "/Date(1629211980000)/", "LastModifiedDateTimeList": null, "PublishedDateStr": "17 Aug 2021", "Summary": "", "MainContent": "<strong>Summary of local situation&nbsp;</strong><br><br>\u2022 As of 17 August 2021, 12pm, the Ministry of Health (MOH) has confirmed and verified that there are 52 cases of locally transmitted COVID-19 infection and 4 imported cases.&nbsp;<br><br>\u2022 404 cases are currently warded in hospital. Most are well and under observation. There are currently 30 cases of serious illness requiring oxygen supplementation, and 6 in critical condition in the intensive care unit (ICU).<br><br>\u2022 Over the last 28 days, the percentage of unvaccinated who became severely ill or died is 9.6%, while that for the fully vaccinated is 1.4%.<br><br>\u2022 As of 16 August 2021, 76% of our population has completed their full regimen/ received two doses of COVID-19 vaccines, and 82% has received at least one dose.<br><div><br><strong>Update on vaccination progress</strong><br><br>As of 16 August 2021, we have administered a total of 8,464,972 doses of COVID-19 vaccines under the national vaccination programme (Pfizer-BioNTech Comirnaty and Moderna), covering 4,440,268 individuals, with 4,155,680 individuals having completed the full vaccination regimen.&nbsp;<br><br>2. In addition, 151,089 doses of other vaccines recognised in the World Health Organization\u2019s Emergency Use Listing (WHO EUL) have been administered as of 16 August 2021, covering 83,968&nbsp;individuals. In total, 76% of our population has completed their full regimen/ received two doses of COVID-19 vaccines, and 82% has received at least one dose.<br><div><br></div><strong><span style=\"text-decoration: underline;\">Figure 1:</span></strong> Percentage of Total Population who Received At Least First Dose<sup>1</sup> and Completed Full Regimen<sup>2</sup> of NVP and WHO EUL Vaccines<sup>3</sup><br><br><a href=\"/images/librariesprovider5/covid-19-chart-(pr)/figure1_17aug2021.png?sfvrsn=1facfa97_0\"><img src=\"/images/librariesprovider5/covid-19-chart-(pr)/figure1_17aug2021.png?sfvrsn=1facfa97_0\" data-displaymode=\"Original\" alt=\"Figure1_17aug2021\" title=\"Figure1_17aug2021\" data-openoriginalimageonclick=\"true\"></a><br><br><strong><span style=\"text-decoration: underline;\">Figure 2:</span></strong> Percentage of Vaccinated Individuals who Received At Least First Dose of NVP and WHO EUL Vaccines by Age Group<br><br><a href=\"/images/librariesprovider5/covid-19-chart-(pr)/figure2_17aug2021.png?sfvrsn=9333d0e5_0\"><img src=\"/images/librariesprovider5/covid-19-chart-(pr)/figure2_17aug2021.png?sfvrsn=9333d0e5_0\" data-displaymode=\"Original\" alt=\"Figure2_17aug2021\" title=\"Figure2_17aug2021\" data-openoriginalimageonclick=\"true\"></a><br><br><strong><span style=\"text-decoration: underline;\">Figure 3:</span></strong> Percentage of Individuals who Completed Full Regimen of NVP and WHO EUL Vaccines by Age Group<br><br><a href=\"/images/librariesprovider5/covid-19-chart-(pr)/figure3_17aug2021.png?sfvrsn=13329edf_0\"><img src=\"/images/librariesprovider5/covid-19-chart-(pr)/figure3_17aug2021.png?sfvrsn=13329edf_0\" data-displaymode=\"Original\" alt=\"Figure3_17aug2021\" title=\"Figure3_17aug2021\" data-openoriginalimageonclick=\"true\"></a><br><strong>Condition of hospitalised cases</strong><br><br>3. 404 cases are currently warded in hospital. There are currently 30 cases of serious illness requiring oxygen supplementation, and 6 in critical condition in the ICU. Of those who have fallen very ill, 31 are seniors above 60 years, of whom 25 are completely unvaccinated or partially vaccinated.&nbsp;&nbsp;<br><br>4. Case 67329, a 90 year-old male Singaporean, has passed away from complications due to COVID-19 infection on 17 August 2021. He had developed symptoms on 29 July, and was detected when he was tested for COVID-19 on 1 August as part of our community surveillance testing. The following day, he developed shortness of breath and giddiness, and was conveyed to Tan Tock Seng Hospital where he was admitted directly to the ICU for septic shock from COVID-19 pneumonia. He had been fully vaccinated against COVID-19, but was advanced in age and had a history of chronic kidney disease and hypertension.&nbsp;<br><br>5. In total, 45 have passed away from complications due to COVID-19 infection.<br><div><br></div><strong><span style=\"text-decoration: underline;\">Figure 4:</span></strong> Number of Active Cases in ICU or Requiring Oxygen Supplementation<br><br><a href=\"/images/librariesprovider5/covid-19-chart-(pr)/figure4_17aug2021.png?sfvrsn=6b837f33_0\"><img src=\"/images/librariesprovider5/covid-19-chart-(pr)/figure4_17aug2021.png?sfvrsn=6b837f33_0\" data-displaymode=\"Original\" alt=\"Figure4_17aug2021\" title=\"Figure4_17aug2021\" data-openoriginalimageonclick=\"true\"></a><br><br><br><strong><span style=\"text-decoration: underline;\">Figure 5:</span></strong> Deaths and Active Cases in ICU or Requiring Oxygen Supplementation, by Age Group<br><div><br></div><a href=\"/images/librariesprovider5/covid-19-chart-(pr)/figure5_17aug2021.png?sfvrsn=95081c07_0\"><img src=\"/images/librariesprovider5/covid-19-chart-(pr)/figure5_17aug2021.png?sfvrsn=95081c07_0\" data-displaymode=\"Original\" alt=\"Figure5_17aug2021\" title=\"Figure5_17aug2021\" data-openoriginalimageonclick=\"true\"></a><br><br><br>6. There is continuing evidence that almost all fully-vaccinated individuals do not suffer serious disease when infected, unless if they had underlying medical conditions that made them more susceptible. Over the last 28 days, the percentage of unvaccinated who became severely ill or died is 9.6%, while that for the fully vaccinated is 1.4%.<br><br><strong><span style=\"text-decoration: underline;\">Figure 6:</span></strong> Local Cases in the Last 28 Days by Vaccination Status &amp; Severity of Condition<sup>4</sup><br><br><a href=\"/images/librariesprovider5/covid-19-chart-(pr)/figure6_17aug2021.png?sfvrsn=9f62212b_0\"><img src=\"/images/librariesprovider5/covid-19-chart-(pr)/figure6_17aug2021.png?sfvrsn=9f62212b_0\" data-displaymode=\"Original\" alt=\"Figure6_17aug2021\" title=\"Figure6_17aug2021\" data-openoriginalimageonclick=\"true\"></a><br><br><strong><span style=\"text-decoration: underline;\">Figure 7:</span></strong> Deaths and Active Cases in ICU or Requiring Oxygen Supplementation, by Vaccination Status<br><br><a href=\"/images/librariesprovider5/covid-19-chart-(pr)/figure7_17aug2021.png?sfvrsn=2d209e3e_0\"><img src=\"/images/librariesprovider5/covid-19-chart-(pr)/figure7_17aug2021.png?sfvrsn=2d209e3e_0\" data-displaymode=\"Original\" alt=\"Figure7_17aug2021\" title=\"Figure7_17aug2021\" data-openoriginalimageonclick=\"true\"></a><br><br><br><div><strong>Locally transmitted COVID-19 cases</strong><br><br>7. There are 52 cases of locally transmitted COVID-19 infection today. 35 are linked to previous cases, and have already been placed on quarantine. 3 are linked to previous cases and were detected through surveillance. 14 are currently unlinked.&nbsp;<br><br>8. There are 4 imported cases, who have already been placed on Stay-Home Notice (SHN) or isolated upon arrival in Singapore. In total, there are 56 new cases of COVID-19 infection in Singapore today.&nbsp;<br><div><br></div></div><strong><span style=\"text-decoration: underline;\">Figure 8:</span></strong> Number of Local Unlinked Cases and Linked Cases by Already Quarantined/ Detected through Surveillance<sup>5</sup><br><br><a href=\"/images/librariesprovider5/covid-19-chart-(pr)/figure8_17aug2021.png?sfvrsn=f43e6fc4_0\"><img src=\"/images/librariesprovider5/covid-19-chart-(pr)/figure8_17aug2021.png?sfvrsn=f43e6fc4_0\" data-displaymode=\"Original\" alt=\"Figure8_17aug2021\" title=\"Figure8_17aug2021\" data-openoriginalimageonclick=\"true\"></a><br><br><strong>Summary of trends for local cases<br></strong><br>9. Overall, the number of new cases in the community has decreased from 481 cases in the week before to 322 cases in the past week. The number of unlinked cases in the community has also decreased from 135 cases in the week before to 91 cases in the past week. The 7-day moving average number of all linked community cases and all unlinked community cases are 33.0 and 13.0 respectively.<br><br><strong><span style=\"text-decoration: underline;\">Figure 9:</span></strong> 7 Day Moving Average Number of Community Unlinked and Linked Cases<sup>5</sup><br><div><br></div><a href=\"/images/librariesprovider5/covid-19-chart-(pr)/figure9_17aug2021.png?sfvrsn=b0794a28_0\"><img src=\"/images/librariesprovider5/covid-19-chart-(pr)/figure9_17aug2021.png?sfvrsn=b0794a28_0\" data-displaymode=\"Original\" alt=\"Figure9_17aug2021\" title=\"Figure9_17aug2021\" data-openoriginalimageonclick=\"true\"></a><br><br><strong><span style=\"text-decoration: underline;\">Figure 10:</span></strong> Local Cases in the Last 14 Days by Age Group and Vaccination Status<br><br><a href=\"/images/librariesprovider5/covid-19-chart-(pr)/figure10_17aug2021.png?sfvrsn=b0c33eed_0\"><img src=\"/images/librariesprovider5/covid-19-chart-(pr)/figure10_17aug2021.png?sfvrsn=b0c33eed_0\" data-displaymode=\"Original\" alt=\"Figure10_17aug2021\" title=\"Figure10_17aug2021\" data-openoriginalimageonclick=\"true\"></a><br><br><strong>Summary of trends for imported cases</strong><br><br>10. There are a total of 4 imported cases. Of these, 3 were detected upon arrival in Singapore, while 1 developed the illness during SHN or isolation.&nbsp;<br><br><strong><span style=\"text-decoration: underline;\">Figure 11:</span></strong> Number of Imported Cases by Detected Upon Arrival/&nbsp;Detected during SHN or Isolation<br><div><br></div><a href=\"/images/librariesprovider5/covid-19-chart-(pr)/figure11_17aug2021.png?sfvrsn=b9eaf007_0\"><img src=\"/images/librariesprovider5/covid-19-chart-(pr)/figure11_17aug2021.png?sfvrsn=b9eaf007_0\" data-displaymode=\"Original\" alt=\"Figure11_17aug2021\" title=\"Figure11_17aug2021\" data-openoriginalimageonclick=\"true\"></a><br><br><br><strong>Active clusters under monitoring</strong><br><br>11. There are no new clusters today, and 6 clusters have closed. There are currently 93 active clusters, ranging between 3 and 1,155 infections.<br><div><br><strong><span style=\"text-decoration: underline;\">Figure 12:</span></strong> Number of Active Clusters<br></div><br><a href=\"/images/librariesprovider5/covid-19-chart-(pr)/figure12_17aug2021.png?sfvrsn=f6aa1246_0\"><img src=\"/images/librariesprovider5/covid-19-chart-(pr)/figure12_17aug2021.png?sfvrsn=f6aa1246_0\" data-displaymode=\"Original\" alt=\"Figure12_17aug2021\" title=\"Figure12_17aug2021\" data-openoriginalimageonclick=\"true\"></a><br><strong><span style=\"text-decoration: underline;\">Figure 13:</span></strong> List of Active Clusters<br><br><br><table border=\"1\" cellspacing=\"0\" cellpadding=\"0\"> <thead> <tr> <td width=\"558\" valign=\"top\"> <p align=\"center\"><strong>Cluster</strong></p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\"><strong>New Cases</strong></p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\"><strong>Total<sup>6</sup></strong></p> </td> </tr> </thead> <tbody><tr> <td width=\"558\"> <p>43 Sungei Kadut Loop dormitory</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">1</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">14</p> </td> </tr> <tr> <td width=\"558\"> <p>Sengkang Bus Interchange staff</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">2</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">19</p> </td> </tr> <tr> <td width=\"558\"> <p>My First Skool (54 Chin Swee Road) </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">2</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">36</p> </td> </tr> <tr> <td width=\"558\"> <p>Chee Song Frozen Foods </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">1</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">8 </p> </td> </tr> <tr> <td width=\"558\"> <p>Case 67651 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">1</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">9</p> </td> </tr> <tr> <td width=\"558\"> <p>Westlite Juniper Dormitory </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">13</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">65</p> </td> </tr> <tr> <td width=\"558\"> <p>North Bridge Road Market &amp; Food Centre </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">1</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">16</p> </td> </tr> <tr> <td width=\"558\"> <p>Bishan Bus Interchange staff</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">15</p> </td> </tr> <tr> <td width=\"558\"> <p>Kian Hiap Construction </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">17</p> </td> </tr> <tr> <td width=\"558\"> <p>SAFRA Tampines </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">17</p> </td> </tr> <tr> <td width=\"558\"> <p>Sin Ming 23 Coffee Shop</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">17</p> </td> </tr> <tr> <td width=\"558\"> <p>Superland Pre-School (Kreta Ayer Community Centre) </p> </td> <td width=\"172\"> <p align=\"center\">0</p> </td> <td width=\"172\"> <p align=\"center\">15</p> </td> </tr> <tr> <td width=\"558\"> <p>Marina Bay Sands Casino </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">66</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 67143 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">4</p> </td> </tr> <tr> <td width=\"558\"> <p>KTV lounges/clubs</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">253</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 67302</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">3</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 68131 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">4</p> </td> </tr> <tr> <td width=\"558\"> <p>Zuellig Pharma</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">12</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 66567 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">34 </p> </td> </tr> <tr> <td width=\"558\"> <p>Westlite Mandai Dormitory </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">14 </p> </td> </tr> <tr> <td width=\"558\"> <p>Case 66838 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">4</p> </td> </tr> <tr> <td width=\"558\"> <p>Jurong Fishery Port/ Hong Lim Market &amp; Food Centre*<em> </em></p> </td> <td width=\"172\"> <p align=\"center\">0</p> </td> <td width=\"172\"> <p align=\"center\">1,155</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 67045 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">3</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 67353 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">5</p> </td> </tr> <tr> <td width=\"558\"> <p>NKF Dialysis Centre (Sakyadhita)</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">9</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 67982 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">7</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 67981 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">3</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 66215 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">6 </p> </td> </tr> <tr> <td width=\"558\"> <p>Case 67343 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">40 </p> </td> </tr> <tr> <td width=\"558\"> <p>Samy\u2019s Curry Restaurant </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">61</p> </td> </tr> <tr> <td width=\"558\"> <p>Punggol Primary School </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">17 </p> </td> </tr> <tr> <td width=\"558\"> <p>Elsie\u2019s Kitchen </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">6</p> </td> </tr> <tr> <td width=\"558\"> <p>Jem</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">6</p> </td> </tr> <tr> <td width=\"558\"> <p>CHIJ Katong Convent </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">10</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 66449</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">21</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 67704 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">4</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 67283 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">12 </p> </td> </tr> <tr> <td width=\"558\"> <p>Case 66244</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">8 </p> </td> </tr> <tr> <td width=\"558\"> <p>Case 67425 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">5 </p> </td> </tr> <tr> <td width=\"558\"> <p>Home\u2019s Favourite Pte Ltd </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">16 </p> </td> </tr> <tr> <td width=\"558\"> <p>Case 67738 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">3</p> </td> </tr> <tr> <td width=\"558\"> <p>Nimble/Knead </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">7</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 66542 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">4</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 67436 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">7</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 67582 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">9</p> </td> </tr> <tr> <td width=\"558\"> <p>Changi General Hospital </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">4</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 66764 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">4</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 66804 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">6</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 66844 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">9</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 67278 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">5</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 67276 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">7</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 67476 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">6</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 66998<em> </em></p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">4</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 65687</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">3</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 66996 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">3</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 67161</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">3</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 67388 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">3</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 67471 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">5</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 67534</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">4</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 67041 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">6</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 67051 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">5</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 66707</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">5</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 66766 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">3</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 66922 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">3</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 67014 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">3</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 67069 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">3</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 67236 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">3</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 66774 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">7</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 67048 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">8</p> </td> </tr> <tr> <td width=\"558\"> <p>Institution S2 Selarang Park Complex<em> </em></p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">8</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 65972</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">4</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 66940 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">4</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 67017 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">3</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 67078 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">3</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 67227 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">3</p> </td> </tr> <tr> <td width=\"558\"> <p>Seng Leong Steel (Ent) Pte Ltd </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">5</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 66754 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">5</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 67085 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">4</p> </td> </tr> <tr> <td width=\"558\"> <p>Yishun Community Hospital </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">4</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 65751</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">8</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 66464 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">7</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 64697</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">76</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 66293</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">3</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 66142</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">3</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 66538 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">4</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 66468 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">3</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 66377</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">5</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 65893 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">6</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 65360 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">10</p> </td> </tr> <tr> <td width=\"558\"> <p>Apex Medical Centre (Jurong)</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">3</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 65979</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">3</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 65791</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">4</p> </td> </tr> <tr> <td width=\"558\"> <p>Case 65342 </p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">0</p> </td> <td width=\"172\" valign=\"top\"> <p align=\"center\">3</p> </td> </tr> </tbody></table> <div><br>* Yuhua Market &amp; Hawker Centre is currently linked to this cluster.<br clear=\"all\"> <div id=\"ftn1\"> <p><br>12. Please refer to MOH\u2019s daily Situation Report (<a href=\"https://covidsitrep.moh.gov.sg/\" title=\"\" class=\"\" target=\"\">www.moh.gov.sg/covid-19/situation-report</a>) for details.<br><br>[1] Based on National Immunisation Registry data.&nbsp;<br></p></div></div>[2] Full regimen refers to individuals who have received both doses of the vaccine or one dose for vaccinated recovered individuals.<br><br>[3] Other vaccines recognised in the WHO EUL account for about 2% of the total population who received at least 1 dose and about 1% of total population who completed the full regimen.<br><div><br>[4] Fully vaccinated - more than 14 days after completing vaccination regimen (both doses of the vaccine or one dose for recovered individuals). Partially vaccinated \u2013 received 1 dose of 2-dose vaccine or COVID-positive within 14 days of completing vaccination regimen.<br><br>[5]&nbsp;Incorporates re-classifications of earlier reported cases.<br></div><br>[6] Includes new cases added today.<br></div>", "PressCategory": ["Press Releases", "Highlights"], "CustomDetailUrl": "", "UrlName": "update-on-local-covid-19-situation-and-vaccination-progress-(17-august-2021)", "CurrentPageUrl": null, "CustomPressWidgetLocationUrl": null}, {"Title": "Government Enhances Subsidies to Improve Affordability of Cancer Treatment", "PublishedDate": "/Date(1629194400000)/", "LastModifiedDateTimeList": null, "PublishedDateStr": "17 Aug 2021", "Summary": "", "MainContent": "<p style=\"margin-top: 0cm; margin-bottom: 0cm; font-size: medium; text-align: justify;\"><span style=\"font-family: Arial;\">&nbsp; &nbsp;The Government has accepted the MediShield Life Council\u2019s recommendations to (a) create a list of clinically proven and cost-effective outpatient cancer drug treatments,&nbsp;(b) allow these cancer drug treatments to be claimable under MediShield Life, and (c) set more granular claim limits to provide better coverage based on the cost of each treatment.&nbsp;The list will cover 90% of existing treatments in the public sector, including some commonly used treatments that do not meet the clinical and cost effectiveness criteria but are grandfathered onto the list.<br><br></span></p><p style=\"text-align: justify;\"><span style=\"font-family: Arial; font-size: 16px;\">2. &nbsp; &nbsp; These recommendations are in line with the approaches in other developed countries such as the UK, Australia and South Korea. They will support the procurement of cancer drugs at better prices and help to keep MediShield Life premiums sustainable. MediSave withdrawal limits and Integrated Shield Plan (IP) coverage will also be aligned to this framework.<br><br>3. &nbsp; &nbsp; At the same time, the Government will subsidise more cancer drug treatments and&nbsp;extend Medication Assistance Fund (MAF) subsidies to more Singaporeans by raising the eligible income criteria. <br><br>4. &nbsp; &nbsp; The combined effect of these changes is that cancer patients will pay less for clinically proven and cost-effective cancer drug treatments.&nbsp;Close to 90% of subsidised Singaporean patients who use these treatments will have their cancer drug bills fully covered by subsidy and MediShield Life, subject to co-payment which can be paid using MediSave. In comparison, under today\u2019s system, 70% of all subsidised Singaporean patients on cancer drug treatments have their bills fully covered.<br><br>5. &nbsp; &nbsp; There is a small proportion of patients who may find that their current treatment will either no longer be claimable or have the claim limit lowered with no subsidy extended. These changes will therefore be implemented only in September 2022, to allow sufficient time for&nbsp;existing patients&nbsp;to complete their current course of treatment and adjust their treatment plans, where needed, to another treatment that is efficacious, cost-effective and eligible for MediShield Life claims and subsidies. The&nbsp;adjustments to IP coverage will be implemented in April 2023, giving insurers more time to implement the changes required.<br><br><strong>MediShield Life Council\u2019s Recommendations<br></strong><br>6. &nbsp; &nbsp; The MediShield Life Council appointed a Cancer Drug Committee, comprising senior oncologists from the public and private sectors, to review MediShield Life\u2019s coverage of cancer drug treatments&nbsp;to support Singaporeans\u2019 continued access to good and affordable care, amidst rising cancer prevalence and the emergence of higher cost cancer drug therapies. The Government has accepted the recommendations of the Council, which&nbsp;are also in line with the approaches in other&nbsp;developed countries with advanced healthcare systems&nbsp;such as UK, Australia and South Korea.<br><br>7. &nbsp; &nbsp; Currently, patients can claim up to $3,000 per month under MediShield Life for all outpatient cancer drug treatments and related services. This has the unintended effect of raising cancer drug prices to maximise the claims. The Council has therefore recommended that MediShield Life should cover a positive list of clinically proven and cost-effective cancer drug treatments, with more granular claim limits ranging from $200 to $9,600 per month to be better aligned to the different costs of cancer drug treatments. This will support procurement of cancer drugs at better prices, and enable better targeted coverage including higher claims limits where the treatment is clinically appropriate and cost effective. A separate claim limit for outpatient cancer drug services has also been recommended to cover other costs that patients incur, such as scans, blood tests and doctor consultations.<br><br>8. &nbsp; &nbsp; About 90% of the existing cancer drug treatments used in the public sector will be included in the positive list. This may include treatments that are common today but are not registered with the Health Sciences Authority or are not cost-effective. They will be assigned a claim limit similar to their&nbsp;subsidised alternatives, including generics and biosimilars, where available. Patients are strongly encouraged to discuss with their doctors on the use of available clinically proven and cost-effective treatments for their conditions.<br><br>9. &nbsp; &nbsp; The Council\u2019s full report can be found in&nbsp;<a href=\"/docs/librariesprovider5/default-document-library/annex-a12145e9763d74fe587ad80b942d86fdb.pdf?sfvrsn=f1c311a9_0\" title=\"Annex A\">Annex A</a>. The positive list of&nbsp;cancer drug treatments that are claimable under MediShield Life&nbsp;can be found at&nbsp;<a href=\"https://www.moh.gov.sg/home/our-healthcare-system/medishield-life/what-is-medishield-life/what-medishield-life-benefits/outpatient-cancer-drug-list\" title=\"\" class=\"\" target=\"\">here</a>, and will be updated every four months to keep up with medical advancements.[1] <br><br>10. &nbsp; &nbsp; Dr Tan Yew Oo, Chairman of the Cancer Drug Committee and Member of the MediShield Life&nbsp;Councilsaid, \u201cRecent developments in malignant haematology and medical oncology such as the discovery of targetable genes&nbsp;and development of immune checkpoint inhibitors have resulted in a significant increase in the cost of cancer drug treatments. Many patients are prescribed these novel therapies alone or in combination with chemotherapy drugs for some cancer types. In some instances,&nbsp;there is currently insufficient clinical evidence that these drugs are effective in improving overall survival or duration of response. At the same time, we are paying higher prices for many of the cancer drug treatments in Singapore, compared to regional jurisdictions such as South Korea and Australia. The current MediShield Life claim limit of $3,000 per month is quite blunt and does not incentivise drug manufacturers to offer better prices or encourage the use of clinically proven and cost-effective treatments. The Committee has therefore recommended changes to improve the design of the MediShield Life scheme.\u201d<br><br>11. &nbsp; &nbsp; Mrs Fang Ai Lian, Chairman of the MediShield Life Council said, \u201cThe Council has been looking at how MediShield Life can better support the Government\u2019s healthcare transformation efforts to ensure quality and sustainable healthcare. This will also help to keep MediShield Life premiums affordable for all Singaporeans.&nbsp;Focusing MediShield Life coverage on clinically proven and cost-effective cancer drug treatments will enable Singapore to negotiate for better drug prices and improve affordability for more patients.The Council recognises the concerns raised by patients during the focus group discussions that the positive list may limit treatment options. To provide greater assurance to patients who are already going through a challenging period, the Council has recommended that existing cancer drug treatments that are commonly used in the public sector be considered for inclusion in the positive list, even if they are not cost-effective.\u201d<br><br><strong>Subsidy Enhancements for all MAF drugs</strong><br><br>12. &nbsp; &nbsp; Subsidised patients in the public healthcare institutions currently receive up to 75% subsidy for drugs under the Standard Drug List (SDL) and MAF[2].&nbsp;Following price negotiations with drug manufacturers to achieve better drug prices and cost-effectiveness, 55 more cancer drugs will be listed under the SDL/MAF, which will increase support for around 150 cancer drug treatments. The new MediShield Life claim limits for cancer drug treatments will be set based on post-subsidy bills.<br><br>13. &nbsp; &nbsp; MAF subsidies will be enhanced with subsidies of up to 50% extended to Singaporeans with per capita household income (PCHI) between $2,800 and $6,500 per month (See&nbsp;<span style=\"text-decoration: underline;\">Table 1</span>), who do not enjoy subsidies today. This subsidy enhancement will improve affordability for eligible patients, and will apply to both cancer and non-cancer drugs listed on MAF.<br></span></p><p align=\"center\"><u>Table 1: Current and Revised Subsidy Framework for MAF</u></p><table border=\"1\" cellspacing=\"0\" cellpadding=\"0\"><tbody><tr><td width=\"288\" rowspan=\"2\" valign=\"top\"><p><strong>Monthly PCHI</strong></p></td><td width=\"312\" colspan=\"2\" valign=\"top\"><p align=\"center\"><strong>Subsidy Tier (Singapore Citizens)</strong></p></td></tr><tr><td width=\"156\" valign=\"top\"><p align=\"center\"><strong>Current</strong></p></td><td width=\"156\" valign=\"top\"><p align=\"center\"><strong>Revised</strong></p></td></tr><tr><td width=\"288\"><p>$0\u2264PCHI\u2264$2,000</p></td><td width=\"312\" colspan=\"2\" valign=\"top\"><p align=\"center\">75%</p></td></tr><tr><td width=\"288\"><p>$2,000 &lt; PCHI\u2264$2,800</p></td><td width=\"312\" colspan=\"2\" valign=\"top\"><p align=\"center\">50%</p></td></tr><tr><td width=\"288\"><p>$2,800 &lt; PCHI\u2264$3,300</p></td><td width=\"156\" rowspan=\"3\"><p align=\"center\">0%*</p></td><td width=\"156\" valign=\"top\"><p align=\"center\">50%</p></td></tr><tr><td width=\"288\"><p>$3,300 &lt; PCHI\u2264$6,500</p></td><td width=\"156\" valign=\"top\"><p align=\"center\">40%</p></td></tr><tr><td width=\"288\"><p>PCHI &gt; $6500</p></td><td width=\"156\" valign=\"top\"><p align=\"center\">0%*</p></td></tr></tbody></table><p>* In exceptional deserving cases, MAF may be extended upon appeal.&nbsp;</p><p style=\"text-align: justify;\"><span style=\"font-family: Arial; font-size: 16px;\"><strong>Adjustments to MediSave Withdrawal Limits&nbsp;<br></strong><br>14. &nbsp; &nbsp; The MediSave withdrawal limits for outpatient chemotherapy and outpatient cancer scans will be adjusted in tandem with the MediShield Life changes (see summary in&nbsp;<span style=\"text-decoration: underline;\">Table 2</span>&nbsp;below).<br></span></p><p align=\"center\"><u>Table 2: Current and Revised MediShield Life and MediSave Limits</u></p><table border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"595\"><tbody><tr><td width=\"101\"><p align=\"center\">&nbsp;</p></td><td width=\"230\"><p align=\"center\"><strong>Current</strong></p></td><td width=\"265\" valign=\"top\"><p align=\"center\"><strong>Revised</strong></p></td></tr><tr><td width=\"101\"><p align=\"center\"><strong>MediShield Life</strong></p></td><td width=\"230\" valign=\"top\"><p>$3,000 per month for all cancer drug treatments and services</p><p align=\"center\">&nbsp;</p></td><td width=\"265\"><p>Ranges from $200 to $9,600 per month for cancer drug treatments on the positive list.</p><p>&nbsp;</p><p>Additional$1,200 per year for cancer drug services.</p><p>&nbsp;</p></td></tr><tr><td width=\"101\"><p align=\"center\"><strong>MediSave</strong></p><p align=\"center\">&nbsp;</p></td><td width=\"230\" valign=\"top\"><p>$1,200 per month for all cancer drug treatmentsand services.</p><p>&nbsp;</p><p>Additional$600 per year for cancer scans^.</p></td><td width=\"265\"><p>$1,200 per month for cancer drug treatments with MediShield Life claim limit above $5,400, and $600 per month for other treatments on the positive list.</p><p>&nbsp;</p><p>Additional $600 per year for cancer drug services and/or other cancer scans^.</p></td></tr></tbody></table><p>^ MediSave can also be used for scans for post-treatment monitoring and radiotherapy patients</p><p style=\"text-align: justify;\"><span style=\"font-family: Arial; font-size: 16px;\">15. &nbsp; &nbsp; Please refer to&nbsp;<span style=\"text-decoration: underline;\"><a href=\"/docs/librariesprovider5/default-document-library/annex-b880319b554ef4ba881959cd09d6f32b4.pdf?sfvrsn=40ec52a9_0\" title=\"Annex B\">Annex B</a></span>&nbsp;for detailed illustrations on how bills will be affected by the lower cancer drug prices and the changes in subsidy, MediShield Life, and MediSave coverage.<br><br><strong>Integrated Shield Plan (IP) Coverage</strong><br><br>16. &nbsp; &nbsp; Currently, most IPs provide as-charged coverage for outpatient cancer drug treatments, subject to an overall policy year limit. To ensure that IPs are aligned in encouraging the use of clinically proven and cost-effective cancer drug treatments, IPs will be required to only cover treatments that are on the MediShield Life positive list and set claim limits for each cancer drug treatment. <br><br>17. &nbsp; &nbsp; These changes do not affect IP riders, which are paid for fully in cash. These changes will apply to all IPs sold or renewed from April 2023 onwards. Together with the changes to MediShield Life and MediSave, these moves will help contribute to the affordability of cancer drug treatments and sustainability of premiums in the long run.<br><br>18. &nbsp; &nbsp; The Government thanks the MediShield Life Council, as well as the Cancer Drug Committee, for the comprehensive review.<br><br><strong>MINISTRY OF HEALTH&nbsp;<br>17 AUGUST 2021<br><br><br></strong></span></p><div><span style=\"font-family: Arial; font-size: 13px;\">[1]&nbsp;The positive list will be based on recommendations by the MOH Drug Advisory Committee (DAC),&nbsp;supported by the Agency for Care Effectiveness, Singapore\u2019s national Health Technology Assessment agency.</span><div id=\"ftn2\"><p style=\"text-align: justify;\"><span style=\"font-family: Arial; font-size: 13px;\">[2]&nbsp;Generally, less expensive drugs are listed on the SDL, while more expensive drugs are listed on the MAF where they apply only when prescribed to patients who meet clinical criteria specific to the drug to ensure that their use is cost-effective.&nbsp;</span></p></div></div>", "PressCategory": ["Press Releases", "Highlights"], "CustomDetailUrl": "", "UrlName": "government-enhances-subsidies-to-improve-affordability-of-cancer-treatment_17Aug2021", "CurrentPageUrl": null, "CustomPressWidgetLocationUrl": null}, {"Title": "52 New Cases of Locally Transmitted Covid-19 Infection", "PublishedDate": "/Date(1629129600000)/", "LastModifiedDateTimeList": null, "PublishedDateStr": "17 Aug 2021", "Summary": "", "MainContent": "As of 17 August 2021, 12pm, the Ministry of Health (MOH) has preliminarily confirmed 52 new cases of locally transmitted COVID-19 infection. 35 are linked to previous cases, and have already been placed on quarantine. 3 are linked to previous cases and were detected through surveillance. 14 are currently unlinked. Amongst the cases is 1 senior above 70 years who is unvaccinated, and is at risk of serious illness.<br><br>2.&nbsp; &nbsp; &nbsp; In addition, there are 4 imported cases, who have already been placed on Stay-Home Notice (SHN) or isolated upon arrival in Singapore. 3 were detected upon arrival in Singapore, while 1 developed the illness during SHN or isolation.<br><br>3.&nbsp; &nbsp; &nbsp; In total, there are 56 new cases of COVID-19 infection in Singapore today.<br><br>4.&nbsp; &nbsp; &nbsp; We are still working through the details of the cases, and further updates will be shared via the MOH press release that will be issued tonight.", "PressCategory": ["Press Releases", "Highlights"], "CustomDetailUrl": "", "UrlName": "52-new-cases-of-locally-transmitted-covid-19-infection-17aug2021", "CurrentPageUrl": null, "CustomPressWidgetLocationUrl": null}]}, "pressItemDictionaryCount": 1, "allowPagination": true, "selectedCategoryForPagination": "Press Releases", "sectionsListingOrder": ["Press Releases"], "paginationInfoDictionary": {"Press Releases": {"ItemsPerPage": 10, "CurrentPageIndex": 0, "LastPageIndex": 0}}}